Researchers at Weill Cornell Medicine identified a specific and unique kind of immune cell activity in the lungs of Covid-19 patients that is different from the type of immune cell activity found in other respiratory infections.
Novartis’ IL-1β inhibitor Ilaris (canakinumab) came up short in a Phase III Covid-19 study, the company reported, following an interim analysis of data.
GlaxoSmithKline will move the company’s experimental vaccine against the respiratory syncytial virus (RSV), a cause of pneumonia in toddlers and the elderly, into the final stage of testing after experiencing encouraging mid-stage trial results.
To develop an effective treatment or vaccine for Covid-19, scientists must understand how the immune system is impacted during the disease.
As the world is eagerly awaiting news of an effective and safe vaccine against Covid-19, several companies are moving ahead testing therapeutic antibodies against the disease.
GentiBio closed on a $20 million seed funding led by OrbiMed, Novartis Venture Fund and RA Capital Management. The company also announced exclusive licensing partnerships with Seattle Children’s Research Institute, Benaroya Research Institute at Virginia Mason (BRK), and MIGAL Galilee Research Institute (MIGAL).
Developing an ‘Inverse Vaccine’ for Type 1 Diabetes Published: July 14, 2020 By Chelsea Weidman Burke BioSpace What do you get when you mix certain immune cells with vitamin […]
Kiadis Pharma licensed a previously undisclosed K-NK0004 program to Sanofi covering Kiadis’ proprietary CD38 knock out (CD38KO) K-NK therapeutics for combination with anti-CD38 monoclonal antibodies.
A new study published in the journal Nano Letters showed that cellular nanosponges may be able to inhibit SARS-CoV-2 infectivity within the body, ultimately neutralizing the virus.
Vancouver, Washington-based CytoDyn filed a second clinical trial protocol with the U.S. Food and Drug Administration to treat severely sick COVID-19 patients.
